{"database": "openregs", "table": "documents", "is_view": false, "human_description_en": "where agency_id = \"FDA\", docket_id = \"FDA-1980-N-0038\" and posted_year = 2017 sorted by posted_date descending", "rows": [["FDA-1980-N-0038-0121", "FDA", "FDA-1980-N-0038", "Evaluation of a Topical Steroid Antibiotic Combination (Halcinonide-Neomycin-Amphotericin) in the Treatment of Cutaneous Candidiasis and Inflammatory Dermatoses re: Supplement from National Pharmaceutical Alliance", "Supporting & Related Material", "Background Material", "2017-12-28T05:00:00Z", 2017, 12, null, null, "2017-12-28T17:56:50Z", null, 0, 0, "09000064805b9631"], ["FDA-1980-N-0038-0138", "FDA", "FDA-1980-N-0038", "Certain Topical Anti-Infective Drug Products; Vioform-Hydrocortisone (Iodochlorhydroxyquin and Hydrocortisone) Request of CIBA-GEIGY Corporation for Hearing Vol I re: Supplement from CIBA-GEIGY (Wald, Harkrader & Ross) (Vol 1 of 3)", "Other", "Supplement (SUP)", "2017-12-28T05:00:00Z", 2017, 12, null, null, "2017-12-28T18:11:59Z", null, 0, 0, "09000064805b963e"], ["FDA-1980-N-0038-0150", "FDA", "FDA-1980-N-0038", "Supplement from Burroughs Wellcome Co. (Vol. 3 of 5)", "Supporting & Related Material", "Background Material", "2017-12-28T05:00:00Z", 2017, 12, null, null, "2017-12-28T19:19:03Z", null, 0, 0, "0900006482cd5c29"], ["FDA-1980-N-0038-0156", "FDA", "FDA-1980-N-0038", "Request for Hearing from Clay-Park Labs, Inc.", "Other", "Request for Hearing", "2017-12-28T05:00:00Z", 2017, 12, null, null, "2017-12-28T19:23:17Z", null, 0, 0, "09000064805b964a"], ["FDA-1980-N-0038-0141", "FDA", "FDA-1980-N-0038", "Letter from Miles Laboratories, Inc. to FDA/DDM", "Other", "Letter(s)", "2017-12-28T05:00:00Z", 2017, 12, null, null, "2017-12-28T18:13:51Z", null, 0, 0, "09000064805b963f"], ["FDA-1980-N-0038-0122", "FDA", "FDA-1980-N-0038", "Clinical Evaluation of a New Halcinonide-Antifungal Combination re: Supplement from National Pharmaceutical Alliance", "Supporting & Related Material", "Background Material", "2017-12-28T05:00:00Z", 2017, 12, null, null, "2017-12-28T17:57:25Z", null, 0, 0, "09000064805b9632"], ["FDA-1980-N-0038-0120", "FDA", "FDA-1980-N-0038", "Combined Steroid-Antiinfective Topical Therapy in Common Dermatoses A Double- Blind, Multi-Center Study of Iodochlorhydroxyquin-Hydrocortisone in 277 Patients re: Supplement from National Pharmaceutical Alliance", "Supporting & Related Material", "Background Material", "2017-12-28T05:00:00Z", 2017, 12, null, null, "2017-12-28T17:55:20Z", null, 0, 0, "09000064805b9630"], ["FDA-1980-N-0038-0153", "FDA", "FDA-1980-N-0038", "Answer Letter from Arthur Hull Hayes, Jr. to American Academy of Dermatology, Inc.", "Other", "Answer", "2017-12-28T05:00:00Z", 2017, 12, null, null, "2017-12-28T19:21:20Z", null, 0, 0, "09000064805b9647"], ["FDA-1980-N-0038-0155", "FDA", "FDA-1980-N-0038", "Letter from Linda M. Quinones to American Academy of Dermatology, Inc.", "Other", "Letter(s)", "2017-12-28T05:00:00Z", 2017, 12, null, null, "2017-12-28T19:22:12Z", null, 0, 0, "09000064805b9649"], ["FDA-1980-N-0038-0128", "FDA", "FDA-1980-N-0038", "Iodochlorhydroxyquin-Hydrocortisone Treatment of Fungal Infections re: Supplement from National Pharmaceutical Alliance", "Supporting & Related Material", "Background Material", "2017-12-28T05:00:00Z", 2017, 12, null, null, "2017-12-28T18:00:02Z", null, 0, 0, "09000064805b9638"], ["FDA-1980-N-0038-0148", "FDA", "FDA-1980-N-0038", "Supplement from Burroughs Wellcome Co. (Vol. 1 of 5)", "Other", "Supplement (SUP)", "2017-12-28T05:00:00Z", 2017, 12, null, null, "2020-01-31T06:55:40Z", null, 0, 0, "09000064805b9646"], ["FDA-1980-N-0038-0152", "FDA", "FDA-1980-N-0038", "Supplement from Burroughs Wellcome Co. (Vol. 5 of 5)", "Supporting & Related Material", "Background Material", "2017-12-28T05:00:00Z", 2017, 12, null, null, "2017-12-28T19:19:25Z", null, 0, 0, "0900006482cd4ff8"], ["FDA-1980-N-0038-0151", "FDA", "FDA-1980-N-0038", "Supplement from Burroughs Wellcome Co. (Vol. 4 of 5)", "Supporting & Related Material", "Background Material", "2017-12-28T05:00:00Z", 2017, 12, null, null, "2017-12-28T19:19:13Z", null, 0, 0, "0900006482cd5304"], ["FDA-1980-N-0038-0133", "FDA", "FDA-1980-N-0038", "Supplement from Merck Sharp & Dohme Research Labs (Vol. 1 of 4)", "Other", "Supplement (SUP)", "2017-12-28T05:00:00Z", 2017, 12, null, null, "2017-12-28T18:05:18Z", null, 0, 0, "09000064805b963c"], ["FDA-1980-N-0038-0142", "FDA", "FDA-1980-N-0038", "Withdrawal Letter from Miles Laboratories, Inc.", "Other", "Withdrawal", "2017-12-28T05:00:00Z", 2017, 12, null, null, "2017-12-28T18:19:41Z", null, 0, 0, "09000064805b9640"], ["FDA-1980-N-0038-0147", "FDA", "FDA-1980-N-0038", "Supplement from Mayrand, Inc. Pharmaceuticals", "Other", "Supplement (SUP)", "2017-12-28T05:00:00Z", 2017, 12, null, null, "2020-01-31T06:55:39Z", null, 0, 0, "09000064805b9645"], ["FDA-1980-N-0038-0145", "FDA", "FDA-1980-N-0038", "Supplement from UAD Laboratories, Inc.", "Other", "Supplement (SUP)", "2017-12-28T05:00:00Z", 2017, 12, null, null, "2020-01-31T06:55:40Z", null, 0, 0, "09000064805b9643"], ["FDA-1980-N-0038-0123", "FDA", "FDA-1980-N-0038", "Iodochlorhydroxyquin re: Supplement from National Pharmaceutical Alliance", "Supporting & Related Material", "Background Material", "2017-12-28T05:00:00Z", 2017, 12, null, null, "2017-12-28T17:58:13Z", null, 0, 0, "09000064805b9633"], ["FDA-1980-N-0038-0124", "FDA", "FDA-1980-N-0038", "Topical Vioform-Hydrocortisone in Varicose Ulcer re: Supplement from National Pharmaceutical Alliance", "Supporting & Related Material", "Background Material", "2017-12-28T05:00:00Z", 2017, 12, null, null, "2017-12-28T17:58:38Z", null, 0, 0, "09000064805b9634"], ["FDA-1980-N-0038-0119", "FDA", "FDA-1980-N-0038", "Supplement from National Pharmaceutical Alliance", "Other", "Supplement (SUP)", "2017-12-28T05:00:00Z", 2017, 12, null, null, "2017-12-28T18:02:14Z", null, 0, 0, "09000064805b962f"], ["FDA-1980-N-0038-0131", "FDA", "FDA-1980-N-0038", "Iodochlorohydroxyquinoline (Vioform) Hydrocortisone Cream and Lotion in Superficial Fungus Infections re: Supplement from National Pharmaceutical Alliance", "Supporting & Related Material", "Background Material", "2017-12-28T05:00:00Z", 2017, 12, null, null, "2017-12-28T18:02:02Z", null, 0, 0, "09000064805b963b"], ["FDA-1980-N-0038-0143", "FDA", "FDA-1980-N-0038", "Correction from the Lemmon Company", "Other", "Correction(s)", "2017-12-28T05:00:00Z", 2017, 12, null, null, "2018-01-02T20:45:08Z", null, 0, 0, "09000064805b9641"], ["FDA-1980-N-0038-0140", "FDA", "FDA-1980-N-0038", "Certain Topical Anti-Infective Drug Products; Vioform-Hydrocortisone (Iodochlorhydroxyquin and Hydrocortisone) Request of CIBA-GEIGY Corporation for Hearing Vol II re: Supplement from CIBA-GEIGY (Wald, Harkrader & Ross) (Vol. 3 of 3)", "Supporting & Related Material", "Background Material", "2017-12-28T05:00:00Z", 2017, 12, null, null, "2017-12-28T18:12:50Z", null, 0, 0, "0900006482ceabb3"], ["FDA-1980-N-0038-0125", "FDA", "FDA-1980-N-0038", "Management of Chronic Eczematoid Dermatitis of the Hands re: Supplement from National Pharmaceutical Alliance", "Supporting & Related Material", "Background Material", "2017-12-28T05:00:00Z", 2017, 12, null, null, "2017-12-28T17:59:02Z", null, 0, 0, "09000064805b9635"], ["FDA-1980-N-0038-0137", "FDA", "FDA-1980-N-0038", "The Proposal to Withdraw the New Drug Application for Terra-Cortril Topical Ointment (NDA 61-011, Section 446.567(a)) - Submission of Data for Terra-Cortril Topical Ointment re Supplement from Pfizer Inc.", "Other", "Supplement (SUP)", "2017-12-28T05:00:00Z", 2017, 12, null, null, "2017-12-28T18:11:19Z", null, 0, 0, "09000064805b963d"], ["FDA-1980-N-0038-0144", "FDA", "FDA-1980-N-0038", "Supplement from Marnel Pharmaceuticals, Inc.", "Other", "Supplement (SUP)", "2017-12-28T05:00:00Z", 2017, 12, null, null, "2020-01-31T07:27:06Z", null, 0, 0, "09000064805b9642"], ["FDA-1980-N-0038-0149", "FDA", "FDA-1980-N-0038", "Supplement from Burroughs Wellcome Co. (Vol. 2 of 5)", "Supporting & Related Material", "Background Material", "2017-12-28T05:00:00Z", 2017, 12, null, null, "2020-01-31T06:55:55Z", null, 0, 0, "0900006482cd514a"], ["FDA-1980-N-0038-0146", "FDA", "FDA-1980-N-0038", "Supplement from Dermik Laboratories, Inc.", "Other", "Supplement (SUP)", "2017-12-28T05:00:00Z", 2017, 12, null, null, "2020-01-31T06:55:40Z", null, 0, 0, "09000064805b9644"], ["FDA-1980-N-0038-0154", "FDA", "FDA-1980-N-0038", "Amendment from BYK-Gulden, Inc. (Covington & Burling)", "Other", "Amendment", "2017-12-28T05:00:00Z", 2017, 12, null, null, "2017-12-28T19:21:07Z", null, 0, 0, "09000064805b9648"], ["FDA-1980-N-0038-0127", "FDA", "FDA-1980-N-0038", "Vioform and Hydrocortisone in Dermatologic Therapy re: Supplement from National Pharmaceutical Alliance", "Supporting & Related Material", "Background Material", "2017-12-28T05:00:00Z", 2017, 12, null, null, "2017-12-28T17:59:44Z", null, 0, 0, "09000064805b9637"], ["FDA-1980-N-0038-0132", "FDA", "FDA-1980-N-0038", "Iodochlorhydroxyquin re: Supplement from National Pharmaceutical Alliance", "Supporting & Related Material", "Background Material", "2017-12-28T05:00:00Z", 2017, 12, null, null, "2017-12-28T18:02:51Z", null, 0, 0, "0900006482cead96"], ["FDA-1980-N-0038-0157", "FDA", "FDA-1980-N-0038", "Supplement from Syntex Laboratories (Kleinfeld, Kaplan and Becker)", "Other", "Supplement (SUP)", "2017-12-28T05:00:00Z", 2017, 12, null, null, "2017-12-28T19:24:45Z", null, 0, 0, "09000064805b964b"], ["FDA-1980-N-0038-0134", "FDA", "FDA-1980-N-0038", "Supplement from Merck Sharp & Dohme Research Labs (Vol. 2 of 4)", "Supporting & Related Material", "Background Material", "2017-12-28T05:00:00Z", 2017, 12, null, null, "2017-12-28T18:08:42Z", null, 0, 0, "0900006482ce4983"], ["FDA-1980-N-0038-0135", "FDA", "FDA-1980-N-0038", "Supplement from Merck Sharp & Dohme Research Labs (Vol. 3 of 4)", "Supporting & Related Material", "Background Material", "2017-12-28T05:00:00Z", 2017, 12, null, null, "2017-12-28T18:08:57Z", null, 0, 0, "0900006482ce2f76"], ["FDA-1980-N-0038-0126", "FDA", "FDA-1980-N-0038", "Topical Use of Vioform-Hydrocortisone in Dermatology re: Supplement from National Pharmaceutical Alliance", "Supporting & Related Material", "Background Material", "2017-12-28T05:00:00Z", 2017, 12, null, null, "2017-12-28T17:59:22Z", null, 0, 0, "09000064805b9636"], ["FDA-1980-N-0038-0129", "FDA", "FDA-1980-N-0038", "Clinical Trial - A Comparison of Two Antiseptic and Steroid Creams re: Supplement from National Pharmaceutical Alliance", "Supporting & Related Material", "Background Material", "2017-12-28T05:00:00Z", 2017, 12, null, null, "2017-12-28T18:00:49Z", null, 0, 0, "09000064805b9639"], ["FDA-1980-N-0038-0130", "FDA", "FDA-1980-N-0038", "Treatment of Nummular Eczema re: Supplement from National Pharmaceutical Alliance", "Supporting & Related Material", "Background Material", "2017-12-28T05:00:00Z", 2017, 12, null, null, "2017-12-28T18:01:17Z", null, 0, 0, "09000064805b963a"], ["FDA-1980-N-0038-0136", "FDA", "FDA-1980-N-0038", "Supplement from Merck Sharp & Dohme Research Labs (Vol. 4 of 4)", "Supporting & Related Material", "Background Material", "2017-12-28T05:00:00Z", 2017, 12, null, null, "2017-12-28T18:09:07Z", null, 0, 0, "0900006482ce24be"], ["FDA-1980-N-0038-0139", "FDA", "FDA-1980-N-0038", "Certain Topical Anti-Infective Drug Products; Vioform-Hydrocortisone (Iodochlorhydroxyquin and Hydrocortisone) Request of CIBA-GEIGY Corporation for Hearing Vol I re: Supplement from CIBA-GEIGY (Wald, Harkrader & Ross) (Vol 2 of 3)", "Supporting & Related Material", "Background Material", "2017-12-28T05:00:00Z", 2017, 12, null, null, "2017-12-28T18:12:32Z", null, 0, 0, "0900006482cea3af"], ["FDA-1980-N-0038-0117", "FDA", "FDA-1980-N-0038", "Supplement from E. R. Squibbs & Sons (Vol. 1 of 2)", "Other", "Supplement (SUP)", "2017-12-27T05:00:00Z", 2017, 12, null, null, "2017-12-27T15:18:57Z", null, 0, 0, "09000064805b962e"], ["FDA-1980-N-0038-0110", "FDA", "FDA-1980-N-0038", "Supplement from Lilly Research Laboratories (Vol. 2 of 2)", "Supporting & Related Material", "Background Material", "2017-12-27T05:00:00Z", 2017, 12, null, null, "2017-12-27T14:23:53Z", null, 0, 0, "0900006482ce4fab"], ["FDA-1980-N-0038-0104", "FDA", "FDA-1980-N-0038", "Supplement from Byk-Gilden, Inc. (Vol. 2 of 2)", "Supporting & Related Material", "Background Material", "2017-12-27T05:00:00Z", 2017, 12, null, null, "2017-12-27T14:12:03Z", null, 0, 0, "0900006482cdc3a3"], ["FDA-1980-N-0038-0112", "FDA", "FDA-1980-N-0038", "Supplement from Syntex Laboratories, Inc. (Vol. 3 of 3)", "Supporting & Related Material", "Background Material", "2017-12-27T05:00:00Z", 2017, 12, null, null, "2017-12-27T15:03:07Z", null, 0, 0, "0900006482cd6e93"], ["FDA-1980-N-0038-0113", "FDA", "FDA-1980-N-0038", "Supplement from Syntex Laboratories, Inc. (Vol. 1 of 3)", "Other", "Supplement (SUP)", "2017-12-27T05:00:00Z", 2017, 12, null, null, "2017-12-27T15:19:54Z", null, 0, 0, "09000064805b962c"], ["FDA-1980-N-0038-0103", "FDA", "FDA-1980-N-0038", "Supplement from Byk-Gilden, Inc. (Vol. 1 of 2)", "Other", "Supplement (SUP)", "2017-12-27T05:00:00Z", 2017, 12, null, null, "2017-12-27T15:20:26Z", null, 0, 0, "09000064805b9629"], ["FDA-1980-N-0038-0107", "FDA", "FDA-1980-N-0038", "Request of Dermik Laboratories, Inc., for Withdrawal of Notice of Opportunity for Hearing and Submission in Support of Request for Hearing (Vol. 3 of 4)", "Supporting & Related Material", "Background Material", "2017-12-27T05:00:00Z", 2017, 12, null, null, "2017-12-27T14:20:05Z", null, 0, 0, "0900006482cdcd55"], ["FDA-1980-N-0038-0114", "FDA", "FDA-1980-N-0038", "Supplement from Burroughs Wellcome Co. ( Vol. 1 of 3)", "Other", "Supplement (SUP)", "2017-12-27T05:00:00Z", 2017, 12, null, null, "2020-01-31T06:55:41Z", null, 0, 0, "09000064805b962d"], ["FDA-1980-N-0038-0115", "FDA", "FDA-1980-N-0038", "Supplement from Burroughs Wellcome Co. ( Vol. 2 of 3)", "Supporting & Related Material", "Background Material", "2017-12-27T05:00:00Z", 2017, 12, null, null, "2017-12-27T15:13:21Z", null, 0, 0, "0900006482cd795e"], ["FDA-1980-N-0038-0118", "FDA", "FDA-1980-N-0038", "Supplement from E. R. Squibbs & Sons (Vol. 2 of 2)", "Supporting & Related Material", "Background Material", "2017-12-27T05:00:00Z", 2017, 12, null, null, "2017-12-27T15:18:43Z", null, 0, 0, "0900006482cd81cf"], ["FDA-1980-N-0038-0102", "FDA", "FDA-1980-N-0038", "Letter from the Upjohn Company to FDA/DDM", "Other", "Letter(s)", "2017-12-27T05:00:00Z", 2017, 12, null, null, "2017-12-28T17:51:24Z", null, 0, 0, "09000064805b9627"], ["FDA-1980-N-0038-0105", "FDA", "FDA-1980-N-0038", "Request of Dermik Laboratories, Inc., for Withdrawal of Notice of Opportunity for Hearing and Submission in Support of Request for Hearing (Vol. 1 of 4)", "Other", "Supplement (SUP)", "2017-12-27T05:00:00Z", 2017, 12, null, null, "2017-12-27T14:18:28Z", null, 0, 0, "09000064805b962a"], ["FDA-1980-N-0038-0106", "FDA", "FDA-1980-N-0038", "Request of Dermik Laboratories, Inc., for Withdrawal of Notice of Opportunity for Hearing and Submission in Support of Request for Hearing (Vol. 2 of 4)", "Supporting & Related Material", "Background Material", "2017-12-27T05:00:00Z", 2017, 12, null, null, "2017-12-27T14:18:15Z", null, 0, 0, "0900006482cdc431"], ["FDA-1980-N-0038-0111", "FDA", "FDA-1980-N-0038", "Supplement from Syntex Laboratories, Inc. (Vol. 2 of 3)", "Supporting & Related Material", "Background Material", "2017-12-27T05:00:00Z", 2017, 12, null, null, "2017-12-27T15:02:51Z", null, 0, 0, "0900006482cd7133"], ["FDA-1980-N-0038-0109", "FDA", "FDA-1980-N-0038", "Supplement from Lilly Research Laboratories (Vol. 1 of 2)", "Other", "Supplement (SUP)", "2017-12-27T05:00:00Z", 2017, 12, null, null, "2017-12-27T15:20:05Z", null, 0, 0, "09000064805b962b"], ["FDA-1980-N-0038-0108", "FDA", "FDA-1980-N-0038", "Request of Dermik Laboratories, Inc., for Withdrawal of Notice of Opportunity for Hearing and Submission in Support of Request for Hearing (Vol. 4 of 4)", "Supporting & Related Material", "Background Material", "2017-12-27T05:00:00Z", 2017, 12, null, null, "2017-12-27T14:21:50Z", null, 0, 0, "0900006482cd795d"], ["FDA-1980-N-0038-0116", "FDA", "FDA-1980-N-0038", "Supplement from Burroughs Wellcome Co. ( Vol. 3 of 3)", "Supporting & Related Material", "Background Material", "2017-12-27T05:00:00Z", 2017, 12, null, null, "2017-12-27T15:13:51Z", null, 0, 0, "0900006482cd61ce"], ["FDA-1980-N-0038-0101", "FDA", "FDA-1980-N-0038", "Letter from Buchanan Ingersoll & Rooney PC", "Other", "Letter(s)", "2017-12-26T05:00:00Z", 2017, 12, "2017-12-26T05:00:00Z", null, "2017-12-26T21:04:22Z", null, 0, 0, "0900006482d73f4b"], ["FDA-1980-N-0038-0099", "FDA", "FDA-1980-N-0038", "Combined Steroid-Antiinfective Topical Therapy in Common Dermatoses: A Double-Blind, Multi-Center Study of Iodochlorhydroxyquin-Hydrocortisone in 277 Patients re: Supplemental from Mallard Inc.", "Supporting & Related Material", "Background Material", "2017-12-22T05:00:00Z", 2017, 12, null, null, "2017-12-22T17:22:15Z", null, 0, 0, "09000064805b9625"], ["FDA-1980-N-0038-0093", "FDA", "FDA-1980-N-0038", "Treatment of Nummular Eczema re: Supplemental from Mallard Inc.", "Supporting & Related Material", "Background Material", "2017-12-22T05:00:00Z", 2017, 12, null, null, "2017-12-22T17:15:53Z", null, 0, 0, "09000064805b961f"], ["FDA-1980-N-0038-0097", "FDA", "FDA-1980-N-0038", "Iodochlorhydroxyquin-Hydrocortisone Treatment of Fungal Infections re: Supplemental from Mallard Inc.", "Supporting & Related Material", "Background Material", "2017-12-22T05:00:00Z", 2017, 12, null, null, "2017-12-22T17:20:20Z", null, 0, 0, "09000064805b9623"], ["FDA-1980-N-0038-0082", "FDA", "FDA-1980-N-0038", "Clinical Evaluation of a New Halcinonide-Antifungal Combination re: Supplemental from Ambix Laboratories", "Supporting & Related Material", "Background Material", "2017-12-22T05:00:00Z", 2017, 12, null, null, "2017-12-22T17:01:11Z", null, 0, 0, "09000064805b9615"], ["FDA-1980-N-0038-0077", "FDA", "FDA-1980-N-0038", "Management of Chronic Eczematoid Dermatitis of the Hands re: Supplemental from Ambix Laboratories", "Supporting & Related Material", "Background Material", "2017-12-22T05:00:00Z", 2017, 12, null, null, "2017-12-22T13:28:59Z", null, 0, 0, "09000064805b960e"], ["FDA-1980-N-0038-0096", "FDA", "FDA-1980-N-0038", "Evaluation of a Topical Steroid Antibiotic Combination (Halcinonide-Neomycin-Amphotericin) in the Treatment of Cutaneous Candidiasis and Inflammatory Dermatoses re: Supplemental from Mallard Inc.", "Supporting & Related Material", "Background Material", "2017-12-22T05:00:00Z", 2017, 12, null, null, "2017-12-22T17:19:08Z", null, 0, 0, "09000064805b9622"], ["FDA-1980-N-0038-0076", "FDA", "FDA-1980-N-0038", "Topical Use of Vioform-Hydrocortisone in Dermatology re: Supplemental from Ambix Laboratories", "Supporting & Related Material", "Background Material", "2017-12-22T05:00:00Z", 2017, 12, null, null, "2017-12-22T13:28:11Z", null, 0, 0, "09000064805b960d"], ["FDA-1980-N-0038-0087", "FDA", "FDA-1980-N-0038", "Supplemental from Mallard Inc.", "Other", "Supplement (SUP)", "2017-12-22T05:00:00Z", 2017, 12, null, null, "2017-12-27T15:23:24Z", null, 0, 0, "09000064805b9619"], ["FDA-1980-N-0038-0088", "FDA", "FDA-1980-N-0038", "Iodochlorhydroxyquin re: Supplemental from Mallard Inc.", "Supporting & Related Material", "Background Material", "2017-12-22T05:00:00Z", 2017, 12, null, null, "2017-12-22T17:11:54Z", null, 0, 0, "09000064805b961a"], ["FDA-1980-N-0038-0084", "FDA", "FDA-1980-N-0038", "Vioform and Hydrocortisone in Dermatologic Therapy re: Supplemental from Ambix Laboratories", "Supporting & Related Material", "Background Material", "2017-12-22T05:00:00Z", 2017, 12, null, null, "2017-12-22T17:02:20Z", null, 0, 0, "09000064805b9617"], ["FDA-1980-N-0038-0074", "FDA", "FDA-1980-N-0038", "Supplemental from Ambix Laboratories", "Other", "Supplement (SUP)", "2017-12-22T05:00:00Z", 2017, 12, null, null, "2017-12-22T13:19:43Z", null, 0, 0, "09000064805b960f"], ["FDA-1980-N-0038-0095", "FDA", "FDA-1980-N-0038", "A Therapeutic Armamentarium for the Treatment of Skin Diseases in Industrial Medical Practice re: Supplemental from Mallard Inc.", "Supporting & Related Material", "Background Material", "2017-12-22T05:00:00Z", 2017, 12, null, null, "2017-12-22T17:18:22Z", null, 0, 0, "09000064805b9621"], ["FDA-1980-N-0038-0086", "FDA", "FDA-1980-N-0038", "Iodochlorhydroxyquin re: Supplement from Ambix Laboratories", "Supporting & Related Material", "Background Material", "2017-12-22T05:00:00Z", 2017, 12, null, null, "2017-12-22T17:04:12Z", null, 0, 0, "0900006482ce9ea7"], ["FDA-1980-N-0038-0083", "FDA", "FDA-1980-N-0038", "Iodochlorohydroxyquinoline (Vioform) Hydrocortisone Cream and Lotion in Superficial Fungus Infections re: Supplemental from Ambix Laboratories", "Supporting & Related Material", "Background Material", "2017-12-22T05:00:00Z", 2017, 12, null, null, "2017-12-22T17:01:53Z", null, 0, 0, "09000064805b9616"], ["FDA-1980-N-0038-0098", "FDA", "FDA-1980-N-0038", "Clinical Evaluation of a New Halcinonide-Antifungal Combination re: Supplemental from Mallard Inc.", "Supporting & Related Material", "Background Material", "2017-12-22T05:00:00Z", 2017, 12, null, null, "2017-12-22T17:20:53Z", null, 0, 0, "09000064805b9624"], ["FDA-1980-N-0038-0079", "FDA", "FDA-1980-N-0038", "Iodochlorhydroxyquin-Hydrocortisone Treatment of Fungal Infections re: Supplemental from Ambix Laboratories", "Supporting & Related Material", "Background Material", "2017-12-22T05:00:00Z", 2017, 12, null, null, "2017-12-22T13:30:35Z", null, 0, 0, "09000064805b9611"], ["FDA-1980-N-0038-0085", "FDA", "FDA-1980-N-0038", "Combined Steroid-Antiinfective Topical Therapy in Common Dermatoses: A Double-Blind, Multi-Center Study of Iodochlorhydroxyquin-Hydrocortisone in 277 Patients re: Supplemental from Ambix Laboratories", "Supporting & Related Material", "Background Material", "2017-12-22T05:00:00Z", 2017, 12, null, null, "2017-12-22T17:02:55Z", null, 0, 0, "09000064805b9618"], ["FDA-1980-N-0038-0078", "FDA", "FDA-1980-N-0038", "Evaluation of a Topical Steroid Antibiotic Combination (Halcinonide-Neomycin-Amphotericin) in the Treatment of Cutaneous Candidiasis and Inflammatory Dermatoses re: Supplemental from Ambix Laboratories", "Supporting & Related Material", "Background Material", "2017-12-22T05:00:00Z", 2017, 12, null, null, "2017-12-22T13:29:54Z", null, 0, 0, "09000064805b9610"], ["FDA-1980-N-0038-0091", "FDA", "FDA-1980-N-0038", "Topical Use of Vioform-Hydrocortisone in Dermatology re: Supplemental from Mallard Inc.", "Supporting & Related Material", "Background Material", "2017-12-22T05:00:00Z", 2017, 12, null, null, "2017-12-22T17:13:33Z", null, 0, 0, "09000064805b961d"], ["FDA-1980-N-0038-0092", "FDA", "FDA-1980-N-0038", "Management of Chronic Eczematoid Dermatitis of the Hands re: Supplemental from Mallard Inc.", "Supporting & Related Material", "Background Material", "2017-12-22T05:00:00Z", 2017, 12, null, null, "2017-12-22T17:15:01Z", null, 0, 0, "09000064805b961e"], ["FDA-1980-N-0038-0081", "FDA", "FDA-1980-N-0038", "Clinical Trial - A Comparison of Two Antiseptic and Steroid Creams re: Supplemental from Ambix Laboratories", "Supporting & Related Material", "Background Material", "2017-12-22T05:00:00Z", 2017, 12, null, null, "2017-12-22T13:38:23Z", null, 0, 0, "09000064805b9614"], ["FDA-1980-N-0038-0090", "FDA", "FDA-1980-N-0038", "Iodochlorohydroxyquinoline (Vioform) Hydrocortisone Cream and Lotion in Superficial Fungus Infections re: Supplemental from Mallard Inc.", "Supporting & Related Material", "Background Material", "2017-12-22T05:00:00Z", 2017, 12, null, null, "2017-12-22T17:12:54Z", null, 0, 0, "09000064805b961c"], ["FDA-1980-N-0038-0089", "FDA", "FDA-1980-N-0038", "Topical Vioform-Hydrocortisone in Varicose Ulcer re: Supplemental from Mallard Inc.", "Supporting & Related Material", "Background Material", "2017-12-22T05:00:00Z", 2017, 12, null, null, "2017-12-22T17:12:18Z", null, 0, 0, "09000064805b961b"], ["FDA-1980-N-0038-0100", "FDA", "FDA-1980-N-0038", "Clinical Trial - A Comparison of Two Antiseptic and Steroid Creams re: Supplemental from Mallard Inc.", "Supporting & Related Material", "Background Material", "2017-12-22T05:00:00Z", 2017, 12, null, null, "2017-12-22T17:23:21Z", null, 0, 0, "09000064805b9626"], ["FDA-1980-N-0038-0080", "FDA", "FDA-1980-N-0038", "Topical Vioform-Hydrocortisone in Varicose Ulcer re: Supplemental from Ambix Laboratories", "Supporting & Related Material", "Background Material", "2017-12-22T05:00:00Z", 2017, 12, null, null, "2017-12-22T13:31:22Z", null, 0, 0, "09000064805b9612"], ["FDA-1980-N-0038-0075", "FDA", "FDA-1980-N-0038", "Treatment of Nummular Eczema re: Supplemental from Ambix Laboratories", "Supporting & Related Material", "Background Material", "2017-12-22T05:00:00Z", 2017, 12, null, null, "2017-12-22T13:27:47Z", null, 0, 0, "09000064805b960c"], ["FDA-1980-N-0038-0094", "FDA", "FDA-1980-N-0038", "Vioform and Hydrocortisone in Dermatologic Therapy re: Supplemental from Mallard Inc.", "Supporting & Related Material", "Background Material", "2017-12-22T05:00:00Z", 2017, 12, null, null, "2017-12-22T17:17:07Z", null, 0, 0, "09000064805b9620"], ["FDA-1980-N-0038-0040", "FDA", "FDA-1980-N-0038", "Request for Hearing from NMC Laboratories, Inc.", "Other", "Request for Hearing", "2017-12-21T05:00:00Z", 2017, 12, null, null, "2017-12-21T15:28:57Z", null, 0, 0, "09000064805b95da"], ["FDA-1980-N-0038-0034", "FDA", "FDA-1980-N-0038", "Request for Hearing from Ciba-Geigy Corporation (Wald, Harkrader & Ross)", "Other", "Request for Hearing", "2017-12-21T05:00:00Z", 2017, 12, null, null, "2017-12-21T14:04:04Z", null, 0, 0, "09000064805b95d0"], ["FDA-1980-N-0038-0051", "FDA", "FDA-1980-N-0038", "Request for Hearing from Mayrand, Inc. Pharmaceuticals", "Other", "Request for Hearing", "2017-12-21T05:00:00Z", 2017, 12, null, null, "2017-12-21T15:57:53Z", null, 0, 0, "09000064805b95ef"], ["FDA-1980-N-0038-0050", "FDA", "FDA-1980-N-0038", "Request for Hearing from UAD Laboratories, Inc.", "Other", "Request for Hearing", "2017-12-21T05:00:00Z", 2017, 12, null, null, "2017-12-21T15:55:45Z", null, 0, 0, "09000064805b95ed"], ["FDA-1980-N-0038-0071", "FDA", "FDA-1980-N-0038", "Evaluation of A Topical Steroid Antibiotic Combination (Halcinonide-Neomycin-Amphotericin) In The Treatment of Cutaneous Candidiasis & Inflammatory Dermatoses re: Supplement from Hyrex Pharmaceuticals", "Supporting & Related Material", "Background Material", "2017-12-21T05:00:00Z", 2017, 12, null, null, "2017-12-21T19:59:12Z", null, 0, 0, "09000064805b9600"], ["FDA-1980-N-0038-0055", "FDA", "FDA-1980-N-0038", "Letter from FDA to Robert H. Becker, Esq.", "Other", "Letter(s)", "2017-12-21T05:00:00Z", 2017, 12, null, null, "2017-12-21T16:12:54Z", null, 0, 0, "09000064805b95f7"], ["FDA-1980-N-0038-0067", "FDA", "FDA-1980-N-0038", "Iodochlorhydroxyquin-Hydrocortisone Treatment of Fungal Infections re: Supplement from Hyrex Pharmaceuticals", "Supporting & Related Material", "Background Material", "2017-12-21T05:00:00Z", 2017, 12, null, null, "2020-01-31T06:55:41Z", null, 0, 0, "09000064805b9607"], ["FDA-1980-N-0038-0049", "FDA", "FDA-1980-N-0038", "Request for Hearing from Saron Pharmacal", "Other", "Request for Hearing", "2017-12-21T05:00:00Z", 2017, 12, null, null, "2017-12-21T15:54:24Z", null, 0, 0, "09000064805b95eb"], ["FDA-1980-N-0038-0064", "FDA", "FDA-1980-N-0038", "Treatment of Nummular Eczema re: Supplement from Hyrex Pharmaceuticals", "Supporting & Related Material", "Background Material", "2017-12-21T05:00:00Z", 2017, 12, null, null, "2017-12-21T19:39:50Z", null, 0, 0, "09000064805b9604"], ["FDA-1980-N-0038-0063", "FDA", "FDA-1980-N-0038", "Topical Use of Vioform-Hydrocortisone In Dermatology re: Supplement from Hyrex Pharmaceuticals", "Supporting & Related Material", "Background Material", "2017-12-21T05:00:00Z", 2017, 12, null, null, "2017-12-21T19:32:38Z", null, 0, 0, "09000064805b9603"], ["FDA-1980-N-0038-0066", "FDA", "FDA-1980-N-0038", "Vioform and Hydrocortisone in Dermatologic Therapy re: Supplement from Hyrex Pharmaceuticals", "Supporting & Related Material", "Background Material", "2017-12-21T05:00:00Z", 2017, 12, null, null, "2017-12-21T19:43:36Z", null, 0, 0, "09000064805b9606"], ["FDA-1980-N-0038-0065", "FDA", "FDA-1980-N-0038", "Iodochlorohydroxyquinoline (Vioform) Hydrocortisone Cream and Lotion in Superficial Fungus Infections re: Supplement from Hyrex Pharmaceuticals", "Supporting & Related Material", "Background Material", "2017-12-21T05:00:00Z", 2017, 12, null, null, "2017-12-21T19:43:08Z", null, 0, 0, "09000064805b9605"], ["FDA-1980-N-0038-0056", "FDA", "FDA-1980-N-0038", "Request for Hearing from Marnel Pharmaceuticals, Inc.", "Other", "Request for Hearing", "2017-12-21T05:00:00Z", 2017, 12, null, null, "2017-12-21T16:15:45Z", null, 0, 0, "09000064805b95f8"], ["FDA-1980-N-0038-0036", "FDA", "FDA-1980-N-0038", "Request for Hearing from NMC Laboratories, Inc.", "Other", "Request for Hearing", "2017-12-21T05:00:00Z", 2017, 12, null, null, "2017-12-21T14:16:37Z", null, 0, 0, "09000064805b95d3"], ["FDA-1980-N-0038-0073", "FDA", "FDA-1980-N-0038", "Topical Vioform-Hydrocortisone in Varicose Ulcer re: Supplement from Hyrex Pharmaceuticals", "Supporting & Related Material", "Background Material", "2017-12-21T05:00:00Z", 2017, 12, null, null, "2017-12-21T20:00:09Z", null, 0, 0, "0900006482ce9d53"], ["FDA-1980-N-0038-0041", "FDA", "FDA-1980-N-0038", "Request for Hearing from National Pharmaceutical Alliance", "Other", "Request for Hearing", "2017-12-21T05:00:00Z", 2017, 12, null, null, "2017-12-21T15:32:40Z", null, 0, 0, "09000064805b95dc"]], "truncated": false, "filtered_table_rows_count": 152, "expanded_columns": [], "expandable_columns": [[{"column": "docket_id", "other_table": "dockets", "other_column": "id"}, "title"]], "columns": ["id", "agency_id", "docket_id", "title", "document_type", "subtype", "posted_date", "posted_year", "posted_month", "comment_start_date", "comment_end_date", "last_modified", "fr_doc_num", "open_for_comment", "withdrawn", "object_id"], "primary_keys": ["id"], "units": {}, "query": {"sql": "select id, agency_id, docket_id, title, document_type, subtype, posted_date, posted_year, posted_month, comment_start_date, comment_end_date, last_modified, fr_doc_num, open_for_comment, withdrawn, object_id from documents where \"agency_id\" = :p0 and \"docket_id\" = :p1 and \"posted_year\" = :p2 order by posted_date desc limit 101", "params": {"p0": "FDA", "p1": "FDA-1980-N-0038", "p2": "2017"}}, "facet_results": {"agency_id": {"name": "agency_id", "type": "column", "hideable": false, "toggle_url": "/openregs/documents.json?agency_id=FDA&docket_id=FDA-1980-N-0038&posted_year=2017", "results": [{"value": "FDA", "label": "FDA", "count": 152, "toggle_url": "https://regs.datadawn.org/openregs/documents.json?docket_id=FDA-1980-N-0038&posted_year=2017", "selected": true}], "truncated": false}, "document_type": {"name": "document_type", "type": "column", "hideable": false, "toggle_url": "/openregs/documents.json?agency_id=FDA&docket_id=FDA-1980-N-0038&posted_year=2017", "results": [{"value": "Other", "label": "Other", "count": 84, "toggle_url": "https://regs.datadawn.org/openregs/documents.json?agency_id=FDA&docket_id=FDA-1980-N-0038&posted_year=2017&document_type=Other", "selected": false}, {"value": "Supporting & Related Material", "label": "Supporting & Related Material", "count": 68, "toggle_url": "https://regs.datadawn.org/openregs/documents.json?agency_id=FDA&docket_id=FDA-1980-N-0038&posted_year=2017&document_type=Supporting+%26+Related+Material", "selected": false}], "truncated": false}, "posted_year": {"name": "posted_year", "type": "column", "hideable": false, "toggle_url": "/openregs/documents.json?agency_id=FDA&docket_id=FDA-1980-N-0038&posted_year=2017", "results": [{"value": 2017, "label": 2017, "count": 152, "toggle_url": "https://regs.datadawn.org/openregs/documents.json?agency_id=FDA&docket_id=FDA-1980-N-0038", "selected": true}], "truncated": false}}, "suggested_facets": [{"name": "subtype", "toggle_url": "https://regs.datadawn.org/openregs/documents.json?agency_id=FDA&docket_id=FDA-1980-N-0038&posted_year=2017&_facet=subtype"}, {"name": "posted_date", "toggle_url": "https://regs.datadawn.org/openregs/documents.json?agency_id=FDA&docket_id=FDA-1980-N-0038&posted_year=2017&_facet=posted_date"}, {"name": "posted_month", "toggle_url": "https://regs.datadawn.org/openregs/documents.json?agency_id=FDA&docket_id=FDA-1980-N-0038&posted_year=2017&_facet=posted_month"}, {"name": "comment_start_date", "toggle_url": "https://regs.datadawn.org/openregs/documents.json?agency_id=FDA&docket_id=FDA-1980-N-0038&posted_year=2017&_facet=comment_start_date"}, {"name": "posted_date", "type": "date", "toggle_url": "https://regs.datadawn.org/openregs/documents.json?agency_id=FDA&docket_id=FDA-1980-N-0038&posted_year=2017&_facet_date=posted_date"}, {"name": "comment_start_date", "type": "date", "toggle_url": "https://regs.datadawn.org/openregs/documents.json?agency_id=FDA&docket_id=FDA-1980-N-0038&posted_year=2017&_facet_date=comment_start_date"}, {"name": "last_modified", "type": "date", "toggle_url": "https://regs.datadawn.org/openregs/documents.json?agency_id=FDA&docket_id=FDA-1980-N-0038&posted_year=2017&_facet_date=last_modified"}], "next": "2017-12-21T05~3A00~3A00Z,FDA-1980-N-0038-0041", "next_url": "https://regs.datadawn.org/openregs/documents.json?agency_id=FDA&docket_id=FDA-1980-N-0038&posted_year=2017&_next=2017-12-21T05~3A00~3A00Z%2CFDA-1980-N-0038-0041&_sort_desc=posted_date", "private": false, "allow_execute_sql": true, "query_ms": 596.9536569900811, "source": "Federal Register API & Regulations.gov API", "source_url": "https://www.federalregister.gov/developers/api/v1", "license": "Public Domain (U.S. Government data)", "license_url": "https://www.regulations.gov/faq"}